J&J acquired global co-development and Commercialization rights of experimental myeloma gene therapy from a Chinese Start-up Nanjing Legend Biotechnology
Shots:
- Nanjing has received $350M from J&J for the global co-development and Commercialization rights for gene therapy for myeloma under development with Llama DNA. J&J is trying to enter CAR-T therapy market by making this deal
- The U.S. FDA has approved the testing of investigational drug on the US population in May 2018- making it the first gene therapy developed by china to receive an approval. Nanjing plans to initiate the US trial this from Aug 2018
- Legend a unit of GenScript Biotech- a firm that designs artificial genes for drug companies- plans to file it next year with China's FDA for approval as first Chinese CAR-T treatment
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com
